Lactic acidosis and hypoglycemia in a patient with high-grade non-Hodgkin's lymphoma and elevated circulating TNF-α

1996 ◽  
Vol 72 (2) ◽  
pp. 97-99 ◽  
Author(s):  
J. Dürig ◽  
W. Fiedler ◽  
M. de Wit ◽  
M. Steffen ◽  
D. K. Hossfeld
Keyword(s):  
Lactic Acidosis ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
High Grade ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Tnf Α

scholarly journals Refractory Hyperlactatemia and Hypoglycemia in an Adult with Non-Hodgkin’s Lymphoma: A Case Report and Review of the Warburg Effect

2021 ◽  
pp. 1159-1167
Author(s):  
Zainab Al Maqrashi ◽  
Mary Sedarous ◽  
Avinash Pandey ◽  
Catherine Ross ◽  
Ahraaz Wyne
Keyword(s):  
Lactic Acidosis ◽  
Warburg Effect ◽  
Hodgkin’S Lymphoma ◽  
Abdominal Mass ◽  
Hodgkin's Lymphoma ◽  
Type B ◽  
Elderly Male ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
The Warburg Effect

Lactate is a byproduct of anaerobic glycolysis, and hyperlactatemia is commonly seen in critically ill patients. We report a case of an elderly male presenting with undifferentiated constitutional symptoms, anemia, thrombocytopenia, severe lactic acidosis, refractory hypoglycemia, and a newly detected abdominal mass. A dedicated workup ruled out infectious etiologies and revealed metastatic non-Hodgkin’s lymphoma. This study explores etiologies of type B lactic acidosis in oncology patients, with a focus on Warburg’s effect, and its potential for prognostication.

The role of interleukins and the widely studied TNF-α in non-Hodgkin’s lymphoma

2021 ◽  
Vol 38 (5) ◽  
Author(s):  
Kyle P. D’mello ◽  
Lei Zhao ◽  
Erin C. Kaser ◽  
Ziwen Zhu ◽  
Huaping Xiao ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Tnf Α

Intensification of the CHOEP Regimen for High-Grade Non- Hodgkin’s Lymphoma by G-CSF: Feasibility of a 14-Day Regimen

1994 ◽  
Vol 17 (1) ◽  
pp. 69-71 ◽  
Author(s):  
L. Trümper ◽  
Ch. Renner ◽  
M. Nahler ◽  
A. Engert ◽  
P. Koch ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
High Grade ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.

1998 ◽  
Vol 16 (1) ◽  
pp. 27-34 ◽  
Author(s):  
U Tirelli ◽  
D Errante ◽  
M Van Glabbeke ◽  
I Teodorovic ◽  
J C Kluin-Nelemans ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Randomized Study ◽  
Objective Response ◽  
Stage Ii ◽  
Hodgkin's Lymphoma ◽  
High Grade ◽  
Standard Regimen ◽  
European Organization ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

PURPOSE We report the results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group, which compared a chemotherapy regimen specifically devised for elderly patients, ie, etoposide, mitoxantrone, and prednimustine (VMP), versus the standard regimen of cyclophosphamide, doxorobucin, vincristine, and prednisone (CHOP) in patients older than 70 years of age with intermediate- and high-grade non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS Patients older than 70 years of age with stage II, III, or IV intermediate- and high-grade NHL, with an Eastern Cooperative Oncology Group (ECOG) performance status less than 4 and acceptable cardiac, renal, and liver function were randomized to receive six courses of VMP or six courses of CHOP. Between February 1989 and June 1994, 130 patients aged 70 to 93 years (median, 75) were enrolled and 120 were assessable for response, 60 patients in each arm. RESULTS Overall objective response rates were 50% and 77% in VMP- and CHOP-treated patients, respectively (P = .01), while complete response (CR) rates were borderline significant (27% v 45%; P = .06). At 2 years, the progression-free survival (PFS) rate was 25% with VMP versus 55% with CHOP (P = .002) and the overall survival (OS) rate was 30% with VMP versus 65% with CHOP (P = .004). Statistically significant more alopecia and neurologic and gastrointestinal toxicities were reported with CHOP. CONCLUSION CHOP is the standard regimen for patients > or = 70 years of age with stage II to IV intermediate- and high-grade NHL.

Sign in / Sign up

Export Citation Format

Share Document